BR112014016126A2 - compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação de dos mesmos e uso terapêutico dos mesmos - Google Patents
compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação de dos mesmos e uso terapêutico dos mesmosInfo
- Publication number
- BR112014016126A2 BR112014016126A2 BR112014016126A BR112014016126A BR112014016126A2 BR 112014016126 A2 BR112014016126 A2 BR 112014016126A2 BR 112014016126 A BR112014016126 A BR 112014016126A BR 112014016126 A BR112014016126 A BR 112014016126A BR 112014016126 A2 BR112014016126 A2 BR 112014016126A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic use
- fgfr
- preparation
- fgf receptor
- monomer unit
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 108091008794 FGF receptors Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 239000000178 monomer Substances 0.000 abstract 4
- 238000006471 dimerization reaction Methods 0.000 abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 150000005229 pyrazolopyridines Chemical class 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof sanofi abstract the invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fgfr dimerization, having the general formula: m1-l-m2 in which m1 and m2, which may be identical or different, each represent, independently of one another, a monomer unit m and l represents a linker group which links m1 and m2 covalently with the monomer unit which follows: process for the preparation thereof and therapeutic use thereof. resumo patente de invenção: "compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação de dos mesmos e uso terapêutico dos mesmos". a invenção se refere aos novos compostos heterocíclicos que são derivados de pirazolopiridina que induzem à dimerização de fgfr, tendo a fórmula geral: m1-l-m2 em que m1 e m2, que podem ser idênticos ou diferentes, cada qual representa, independentemente um do outro, uma unidade monômera m e l representa um grupo ligador que liga m1 e m2 covalentemente com a unidade monômera que segue (fórmula m). processo para a preparação dos mesmos e uso terapêutico dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1162486A FR2985258A1 (fr) | 2011-12-28 | 2011-12-28 | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| PCT/IB2012/057726 WO2013098763A1 (en) | 2011-12-28 | 2012-12-26 | Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014016126A2 true BR112014016126A2 (pt) | 2017-06-13 |
| BR112014016126A8 BR112014016126A8 (pt) | 2017-07-04 |
Family
ID=47716120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014016126A BR112014016126A8 (pt) | 2011-12-28 | 2012-12-26 | compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação de dos mesmos e uso terapêutico dos mesmos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9206177B2 (pt) |
| EP (1) | EP2797930B1 (pt) |
| JP (1) | JP6049755B2 (pt) |
| KR (1) | KR20140114375A (pt) |
| CN (1) | CN104136444B (pt) |
| AR (1) | AR089483A1 (pt) |
| AU (1) | AU2012360094B9 (pt) |
| BR (1) | BR112014016126A8 (pt) |
| CA (1) | CA2861741C (pt) |
| CY (1) | CY1118997T1 (pt) |
| DK (1) | DK2797930T3 (pt) |
| ES (1) | ES2598083T3 (pt) |
| FR (1) | FR2985258A1 (pt) |
| HK (1) | HK1198648A1 (pt) |
| HR (1) | HRP20161306T1 (pt) |
| HU (1) | HUE029036T2 (pt) |
| IL (1) | IL233325A0 (pt) |
| LT (1) | LT2797930T (pt) |
| MX (1) | MX356658B (pt) |
| PL (1) | PL2797930T3 (pt) |
| PT (1) | PT2797930T (pt) |
| RU (1) | RU2014131014A (pt) |
| SG (2) | SG10201609069YA (pt) |
| SI (1) | SI2797930T1 (pt) |
| TW (1) | TWI582093B (pt) |
| UY (1) | UY34560A (pt) |
| WO (1) | WO2013098763A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MX393494B (es) | 2013-04-19 | 2025-03-24 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| JP6854776B2 (ja) | 2015-01-08 | 2021-04-07 | インぺティス バイオサイエンス リミテッド | 二環式化合物、その組成物および医薬用途 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102409669B1 (ko) * | 2020-11-10 | 2022-06-16 | 아주대학교산학협력단 | 인돌리진 유도체 화합물 및 이를 포함하는 표적 물질 검출용 화합물 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2025037230A1 (en) * | 2023-08-11 | 2025-02-20 | Life Code Limited | Compositions, agents and preparations for promoting hair growth and/or mitigating hair loss |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| AU2003300114B9 (en) * | 2002-12-31 | 2009-11-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
| FR2896247B1 (fr) * | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| DK2194783T3 (en) * | 2007-08-10 | 2017-10-02 | Vm Discovery Inc | COMPOSITIONS AND PROCEDURES FOR APOPTOS MODULATORS |
| EP2270043A1 (en) * | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| FR2962438B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
-
2011
- 2011-12-28 FR FR1162486A patent/FR2985258A1/fr active Pending
-
2012
- 2012-12-26 SG SG10201609069YA patent/SG10201609069YA/en unknown
- 2012-12-26 CA CA2861741A patent/CA2861741C/en not_active Expired - Fee Related
- 2012-12-26 MX MX2014007842A patent/MX356658B/es active IP Right Grant
- 2012-12-26 RU RU2014131014A patent/RU2014131014A/ru not_active Application Discontinuation
- 2012-12-26 LT LTEP12824733.5T patent/LT2797930T/lt unknown
- 2012-12-26 AU AU2012360094A patent/AU2012360094B9/en not_active Ceased
- 2012-12-26 HR HRP20161306TT patent/HRP20161306T1/hr unknown
- 2012-12-26 SI SI201230732A patent/SI2797930T1/sl unknown
- 2012-12-26 PL PL12824733T patent/PL2797930T3/pl unknown
- 2012-12-26 SG SG11201403571QA patent/SG11201403571QA/en unknown
- 2012-12-26 ES ES12824733.5T patent/ES2598083T3/es active Active
- 2012-12-26 CN CN201280070751.XA patent/CN104136444B/zh active Active
- 2012-12-26 HK HK14112112.2A patent/HK1198648A1/xx unknown
- 2012-12-26 HU HUE12824733A patent/HUE029036T2/en unknown
- 2012-12-26 EP EP12824733.5A patent/EP2797930B1/en active Active
- 2012-12-26 BR BR112014016126A patent/BR112014016126A8/pt not_active IP Right Cessation
- 2012-12-26 PT PT128247335T patent/PT2797930T/pt unknown
- 2012-12-26 KR KR1020147019803A patent/KR20140114375A/ko not_active Ceased
- 2012-12-26 DK DK12824733.5T patent/DK2797930T3/en active
- 2012-12-26 US US14/369,144 patent/US9206177B2/en active Active
- 2012-12-26 WO PCT/IB2012/057726 patent/WO2013098763A1/en active Application Filing
- 2012-12-26 JP JP2014549608A patent/JP6049755B2/ja active Active
- 2012-12-27 AR ARP120105003A patent/AR089483A1/es unknown
- 2012-12-28 TW TW101151327A patent/TWI582093B/zh not_active IP Right Cessation
- 2012-12-28 UY UY0001034560A patent/UY34560A/es not_active Application Discontinuation
-
2014
- 2014-06-23 IL IL233325A patent/IL233325A0/en unknown
-
2016
- 2016-10-13 CY CY20161101025T patent/CY1118997T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014016126A2 (pt) | compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação de dos mesmos e uso terapêutico dos mesmos | |
| BR112014015882A2 (pt) | compostos diméricos agonistas de receptor de fgf (fgfr), processo para a preparação dos mesmos e uso terapêutico dos mesmos | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
| AR059001A1 (es) | Compuestos dimeros agonistas de los receptores de los fgf (fgfr) , su proceso de preparacion y su aplicacion en terapeutica. composiciones farmaceuticas. | |
| CY1118735T1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
| CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
| EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| CY1112552T1 (el) | Υδροξυμεθυλο πυρρολιδινες ως αγωνιστες β3 αδρενεργικου υποδοχεα | |
| CY1113315T1 (el) | Ιμιδαζολοκαρβοξαμιδια | |
| CY1120159T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| CY1117638T1 (el) | Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| CY1118721T1 (el) | Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης | |
| BR112014013974A2 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
| BR112015018508A2 (pt) | moduladores de enzimas modificadoras de metila, suas composições e uso | |
| NO20093146L (no) | Amino-pyridinderivater som S1P1/EDG1-reseptoragonister | |
| BR112014032809A2 (pt) | melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas | |
| PA8841701A1 (es) | Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden compuestos y su uso | |
| CY1111747T1 (el) | 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα | |
| GT201400085A (es) | Profármaco de adrenomedulina basado en polietilenglicol y su uso | |
| UY32296A (es) | Nuevos compuestos | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
| UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2546 DE 22-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |